English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aim. To assess the eff ect of anticoagulant therapy on survival and outcome of venous thrombosis in children, teenagers, and young adults with acute lymphoblastic leukemia (ALL). Materials & Methods. Venous thrombosis was diagnosed in 42 out of 592 ALL patients treated according to ALLMB-2008 and ALL-MB-2015 protocols from 2008 to 2017. Results. A daily dose of 150–200 IU/kg low molecular weight heparin (LMWH) was administered to 30 patients. Duration of anticoagulant treatment was up to 1 month in 4 patients, 2–3 months in 8 patients, 4–6 months in 12 patients, and 7–12 months in 4 patients. To 2 patients anticoagulants were administered for more than 24 months. Complete recanalization of thrombosed vessel was achieved in 19 patients, partial recanalization was achieved in 6 patients, obliteration of predominantly internal jugular vein was found in 5 patients. During thrombocytopenia (100 to 35 × 109/L) 12 patients received reduced doses of LMWH for 1–4 weeks. In the period of chemotherapy-induced thrombocytopenia the daily LMWH dose was reduced in proportion to thrombocyte level. After thrombocyte recovery up to more than 100 × 109/L antithrombotic treatment was continued with LMWH daily dose of 150–200 anti-Xa IU/kg. The duration of anticoagulant treatment among 12 patients who received reduced doses of LMWH was up to 1 month in 3 patients, 2–3 months in 4 patients, 4–6 months in 3 patients, and 7–12 months in 2 patients. Complete recanalization of thrombosed vessel was achieved in 8 patients, partial recanalization was achieved in 2 patients, vein obliteration was found in 2 patients. No correlation between LMWH dosage and thrombosis outcome was observed (χ2 = 0.494; p = 0.78). Maintenance (accompanying) therapy was completed in 38 out of 42 ALL patients with venous thrombosis. Event-free 339 ht tp : / /b lood journa l . ru / Лечение венозных тромбозов при ОЛЛ ющую терапию завершило 38. Бессобытийная выживаемость составила 83 ± 8 %, что не отличалось от таковой (81 ± 2 %) у пациентов без тромбозов (p = 0,654). Заключение. Антикоагулянтная терапия, проводимая по поводу венозных тромбозов, осложняющих течение ОЛЛ у детей, подростков и молодых взрослых, не привела к снижению общей и бессобытийной выживаемости. Снижение дозы НМГ в период индуцированной химиотерапией тромбоцитопении не повлияло на исход венозных тромбозов. Ключевые слова: венозный тромбоз, свертывание крови, острый лимфобластный лейкоз, дети, подростки, молодые взрослые, антикоагулянтная терапия, низкомолекулярный гепарин. Получено: 30 октября 2018 г. Принято в печать: 5 июня 2019 г. Для переписки: Вячеслав Васильевич Дмитриев, д-р мед. наук, ул. Фрунзенская, д. 43, д. Боровляны, Минский район, Республика Беларусь, 223053; тел.: +375(17)265-42-22; e-mail: dmitrievhaematol@mail.ru Для цитирования: Дмитриев В.В., Мигаль Н.В., Быданов О.И. и др. Влияние антикоагулянтной терапии на выживаемость и исход венозных тромбозов у детей, подростков и молодых взрослых с острым лимфобластным лейкозом в рамках протоколов ALL-МВ-2008 и ALL-МВ-2015. Клиническая онкогематология. 2019;12(3):338–43. doi: 10.21320/2500-2139-2019-12-3-338-343 survival was 83 ± 8 %, that was similar to the one (81 ± 2 %) in patients without thrombosis (p = 0.654). Conclusion. Anticoagulant treatment of venous thrombosis complicating ALL in children, teenagers, and young adults did not yield a decrease of either overall or event-free survival. Reduction of LMWH doses in the period of chemotherapy-induced thrombocytopenia did not aff ect the outcome of venous thrombosis.

kliničeskaâ onkogematologiâ

The Effect of Anticoagulant Therapy on Survival and Outcome of Venous Thrombosis in Children, Teenagers, and Young Adults with Acute Lymphoblastic Leukemia Treated According to ALL-MB-2008 and ALL-MB-2015 Protocols